Search hospitals
>
Minnesota
>
Minneapolis
Fairview Southdale Hospital
Claim this profile
Minneapolis, Minnesota 55435
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
555 reported clinical trials
16 medical researchers
Summary
Fairview Southdale Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Fairview Southdale Hospital is involved with conducting 555 clinical trials across 565 conditions. There are 16 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Area of expertise
Breast Cancer
Fairview Southdale Hospital has run 102 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Fairview Southdale Hospital has run 82 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
David M. King
Park Nicollet Clinic - Saint Louis Park
9 years of reported clinical research
Daniel M. Anderson
Abbott-Northwestern Hospital
7 years of reported clinical research
Yan Ji
Regions Hospital
2 years of reported clinical research
Pamala A. Pawloski
Park Nicollet Clinic - Saint Louis Park
6 years of reported clinical research
Clinical Trials running at Fairview Southdale Hospital
Lung Cancer
Prostate Cancer
Breast Cancer
Ovarian Cancer
Bladder Cancer
Breast cancer
Colorectal Cancer
Cancer
Kidney Cancer
Esophageal cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Fairview Southdale Hospital?
Fairview Southdale Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Fairview Southdale Hospital is involved with conducting 555 clinical trials across 565 conditions. There are 16 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Fairview Southdale Hospital located?
**Directions to Fairview Southdale Hospital, Minneapolis:** - Take Interstate 35W south to Highway 62 (Crosstown). - Follow Highway 62 west to France Ave and turn left. - Continue for one block to 65th St.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Fairview Southdale Hospital, visit [Fairview Financial Assistance](http://www.fairview.org/billing/fairview-financial-assistance) for policy details and application forms. For assistance or inquiries, contact the Customer Service Center at 612-672-6724. For insurance-related questions and bill payment options (online, by phone, by mail, or in person), refer to the Bill Pay & Financial Resources page.
What insurance does Fairview Southdale Hospital accept?
Fairview Southdale Hospital accepts a wide range of insurance plans, including the 2023 Fairview Medical Plans, which provide local coverage in the 11-county Twin Cities metro area and nationwide coverage. M Health Fairview providers are in-network for many insurance plans. UCare Individual & Family Plans with M Health Fairview feature cost-effective options with access to popular providers in the Twin Cities.
What awards or recognition has Fairview Southdale Hospital received?
Fairview Southdale Hospital, located in Minneapolis, Minnesota, is renowned for its emergency heart attack program and advanced imaging services. It has been named the top hospital in the Twin Cities metro for cardiology and coronary intervention. As part of the M Health Fairview system, it provides access to the University of Minnesota Medical Center's cutting-edge medical research and specialties.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.